Comparative Pharmacology
Head-to-head clinical analysis: LUTREPULSE KIT versus SUPPRELIN LA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LUTREPULSE KIT versus SUPPRELIN LA.
LUTREPULSE KIT vs SUPPRELIN LA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
LUTREPULSE (gonadorelin acetate) is a synthetic decapeptide analog of endogenous gonadotropin-releasing hormone (GnRH). It binds to GnRH receptors on the anterior pituitary gonadotroph cells, stimulating synthesis and release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH). In males, LH stimulates Leydig cells to produce testosterone; in females, LH triggers ovulation and FSH stimulates follicular development.
SUPPRELIN LA is a sterile, biodegradable, subcutaneous implant containing histrelin acetate, a synthetic nonapeptide agonist of gonadotropin-releasing hormone (GnRH). After an initial transient increase, continuous administration results in downregulation of pituitary GnRH receptors, leading to suppressed luteinizing hormone (LH) and follicle-stimulating hormone (FSH) secretion, thereby reducing gonadal sex steroid production (testosterone in males, estradiol in females) to castrate levels.
5 mcg subcutaneously every 90 minutes via pulsatile pump.
50 mg subcutaneously once every 12 months (implant placed in inner upper arm).
None Documented
None Documented
3 hours (initial phase), terminal elimination half-life 10-12 hours; clinically, steady-state reached within 2 days.
Terminal half-life approximately 3-4 hours; clinical suppression of luteinizing hormone and testosterone sustained for 4 weeks due to depot formulation.
Renal: 10% unchanged; hepatic metabolism, metabolites primarily excreted in bile (70%) and feces.
Renal: <5% unchanged; hepatic metabolism; fecal elimination of metabolites.
Category C
Category C
GnRH Agonist
GnRH Agonist